Table 3. Summary of muropeptide composition of LMC500 strains carrying no plasmid or different expression plasmids.
| Muropeptides2 or feature | Percent peak area (%)1 | ||||
|---|---|---|---|---|---|
| LMC500 | LMC500 mKO | LMC500 mKO-PBP2WT | LMC500 mKO-PBP2L61R | LMC500 mKO-GlpT | |
| Monomers (total) | 52.6 ± 0.1 | 52.0 ± 0.0 | 52.1 ± 1.1 | 52.2 ± 0.9 | 52.2 ± 0.0 |
| dipeptides | 1.4 ± 0.0 | 1.6 ± 0.1 | 1.3 ± 0.1 | 1.2 ± 0.0 | 1.4 ± 0.0 |
| tripeptides | 5.0 ± 0.2 | 5.0 ± 0.0 | 5.0 ± 0.5 | 4.0 ± 0.3 | 4.7 ± 0.1 |
| tetrapeptides | 41.6 ± 0.0 | 41.0 ± 0.0 | 41.3 ± 0.5 | 43.3 ± 2.0 | 41.8 ± 0.2 |
| anhydro | 0.9 ± 0.0 | 1.0 ± 0.0 | 1.0 ± 0.0 | 0.7 ± 0.0 | 1.0 ± 0.0 |
| LysArg | 3.7 ± 0.4 | 3.4 ± 0.2 | 3.5 ± 0.5 | 3.0 ± 1.2 | 3.4 ± 0.5 |
| Dimers (total) | 40.5 ± 0.0 | 40.8 ± 0.0 | 40.2 ± 0.7 | 41.7 ± 0.9 | 40.7 ± 0.1 |
| tetratripeptide | 3.1 ± 0.3 | 3.0 ± 0.2 | 3.0 ± 0.1 | 2.2 ± 0.0 | 2.9 ± 0.1 |
| tetratetrapeptide | 36.0 ± 1.0 | 36.3 ± 0.2 | 35.0 ± 2.6 | 37.1 ± 2.7 | 36.0 ± 0.9 |
| anhydro | 2.0 ± 0.0 | 2.1 ± 0.0 | 2.2 ± 0.0 | 1.7 ± 0.0 | 2.0 ± 0.0 |
| LysArg | 1.6 ± 0.0 | 1.7 ± 0.1 | 1.5 ± 0.2 | 1.2 ± 0.2 | 1.6 ± 0.1 |
| Trimers (Total) | 4.4 ± 0.1 | 4.6 ± 0.1 | 4.8 ± 0.0 | 3.8 ± 0.0 | 4.5 ± 0.1 |
| Dipeptides (total) | 1.4 ± 0.0 | 1.6 ± 0.1 | 1.3 ± 0.1 | 1.2 ± 0.0 | 1.4 ± 0.0 |
| Tripeptides (total) | 7.2 ± 0.9 | 7.2 ± 0.2 | 7.6 ± 1.1 | 6.3 ± 0.7 | 7.0 ± 0.3 |
| Tetrapeptides (total) | 85.8 ± 0.1 | 85.8 ± 0.0 | 85.3 ± 0.1 | 87.7 ± 0.0 | 86.2 ± 0.0 |
| Chain ends (anhydro) | 2.3 ± 0.0 | 2.4 ± 0.0 | 2.5 ± 0.0 | 1.9 ± 0.0 | 2.3 ± 0.0 |
| Glycan chain length (DS)3 | 42.8 ± 0.2 | 40.5 ± 0.0 | 38.3 ± 0.1 | 52.1 ± 0.5 | 41.6 ± 0.0 |
| Degree of cross-linkage | 23.2 ± 0.1 | 23.4 ± 0.0 | 23.3 ± 0.1 | 23.3 ± 0.2 | 23.3 ± 0.0 |
| % Peptides in cross-links | 47.4 ± 0.1 | 48.0 ± 0.0 | 48.0 ± 1.1 | 47.8 ± 0.9 | 47.8 ± 0.0 |
1 values are mean ± variation of two biological replicates.
2 muropeptide names according to Glauner, 1988 [60].
3 average glycan chain length in disaccharide (DS) units calculated from the percentage of anhydro-MurNAc containing muropeptides. The bold number highlights the increased average glycan chain length in cells expressing PBP2L61R.